United States PD-1 Antibody Drug Market was valued at USD 18.0 Billion in 2022 and is projected to reach USD 37.8 Billion by 2030, growing at a CAGR of 10.1% from 2024 to 2030.
The PD-1 Antibody Drug market in the United States is experiencing significant growth, driven by the increasing demand for immunotherapy treatments. PD-1 (Programmed Cell Death Protein 1) antibodies are pivotal in the fight against cancer, offering novel therapies for various cancer types, including melanoma, lung cancer, and head and neck cancers. These drugs work by blocking the PD-1 protein on immune cells, thereby enhancing the body’s natural immune response to tumors. This mechanism has led to transformative outcomes in cancer treatment, positioning PD-1 antibody drugs as a critical component in modern oncology.
In recent years, industries have ramped up their requirements for PD-1 antibody drugs due to the proven efficacy and expanding application of these therapies. The pharmaceutical sector, along with biotechnology companies, has been increasingly focused on developing next-generation PD-1 inhibitors. Companies like Merck and Bristol-Myers Squibb have already achieved success with their flagship PD-1 antibody drugs, Keytruda and Opdivo, respectively, which have become standards in cancer treatment regimens. These companies continue to drive innovation through clinical trials, seeking to extend the use of PD-1 antibody drugs to additional cancers and optimize dosing schedules.
The need for these drugs in the market is further highlighted by the rapid advancements in personalized medicine. As more genetic profiling and biomarker-driven treatments are developed, the requirement for targeted immunotherapies like PD-1 antibodies grows. Healthcare providers are also increasingly adopting these therapies due to their potential to significantly improve patient survival rates, especially in advanced-stage cancers that were previously difficult to treat.
Moreover, the growth of the PD-1 antibody drug market is not just limited to large pharmaceutical companies. Biotechnology firms are also entering this lucrative space, focusing on developing novel antibody therapies that could outperform existing treatments. Additionally, regulatory approvals from agencies like the FDA have played a vital role in driving the market forward by endorsing the use of these drugs in multiple cancer types.
Furthermore, the adoption of PD-1 antibody therapies in clinical settings is being facilitated by the growing demand for treatments that can offer better quality of life for cancer patients. The ongoing clinical trials and the expansion of indications for these drugs across various oncology areas contribute to the ever-increasing industry need for PD-1 antibody drugs, ultimately shaping the future of cancer care in the U.S.
Get an In-Depth Research Analysis of the US PD-1 Antibody Drug Market Size And Forecast [2025-2032]
Novartis
Thermo Fisher
InvivoGen
BioVision Inc.
Abcam
Bristol-Myers Squibb
Merck
Ono Pharmaceutical Co.
Ltd
Eli Lilly
Chugai Pharmaceutical Co.
Ltd
BeiGene
AbbVie
TG Therapeutics
Inc
Beijing Yiqiao Shenzhou Technology Co.
Ltd.
3SBio
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US PD-1 Antibody Drug Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US PD-1 Antibody Drug Market
Monoclonal Antibodies
Bispecific Antibodies
Additional Formats (e.g., conjugated antibodies)
PD-1 Inhibitors
PD-L1 Inhibitors
Combination Therapies (PD-1 with other immunotherapeutics)
Non-Small Cell Lung Cancer (NSCLC)
Melanoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
Urothelial Carcinoma
Others (e.g., Hodgkin Lymphoma, Renal Cell Carcinoma)
Intravenous (IV)
Subcutaneous (SC)
Oral
Hospitals
Specialty Clinics
Research Institutions
Home Healthcare Providers
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ PD-1 Antibody Drug Market Research Analysis
1. Introduction of the US PD-1 Antibody Drug Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US PD-1 Antibody Drug Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US PD-1 Antibody Drug Market, By Type
6. US PD-1 Antibody Drug Market, By Application
7. US PD-1 Antibody Drug Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US PD-1 Antibody Drug Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/